✨ Free AI Report
Cara Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Cara Therapeutics, Inc.
Research Preview

Cara Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Cara Therapeutics is a clinical-stage biopharmaceutical company specializing in novel therapeutics for chronic pruritus and pain by targeting peripheral kappa opioid receptors. The company's lead commercialized produc...

Analyst-debate audio for Cara Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Cara Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Cara Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
4/ 10Challenged

Cyborg Score thesis

Early-stage biotech with differentiated mechanism addressing unmet need in pruritus, but faces capital constraints and execution...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals / Specialty Therapeutics
3 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Cara Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Cara Therapeutics, Inc. Overview

Pro stress-test →

Cara Therapeutics is a clinical-stage biopharmaceutical company specializing in novel therapeutics for chronic pruritus and pain by targeting peripheral kappa opioid receptors. The company's lead commercialized product is KORSUVA (difelikefalin) injection, FDA-approved for treating moderate-to-severe pruritus in hemodialysis patients, with an oral formulation in Phase II/III trials for neuropathic pruritus.

Strategic Profile

Pro stress-test →

Cara leverages a differentiated mechanism targeting non-scheduled kappa opioid receptors, offering an alternative to traditional opioids without systemic side effects. The company has established partnerships with major pharma (Vifor Fresenius, Maruishi, Chong Kun Dang) for geographic expansion and commercial development, positioning itself uniquely in an underserved market with limited treatment options.

Competitive Landscape

Pro stress-test →

Cara operates in a specialized pruritus treatment market with limited direct competitors. The company competes with dermatological and pain management therapies that address itch symptoms through different mechanisms. Major players in adjacent pain/inflammation spaces (Allergan, Pfizer, Johnson & Johnson) represent indirect competition, though few have specific pruritus programs targeting kappa receptors.

Industry Context

Cara Therapeutics, Inc. operates in Biopharmaceuticals / Specialty Therapeutics.

Key facts

Founded: 2004 · Headquarters: Stamford, Connecticut · Market cap: $38M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Cara Therapeutics, Inc..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Cara Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Topical corticosteroids and antihistaminesTraditional pruritus treatments with limited efficacy in CKD-related itch→Gabapentin and pregabalinOff-label neuropathic itch treatments lacking FDA indication→Emerging kappa agonist programsEarly-stage competitors pursuing similar peripheral kappa receptor mechanisms→

Compare Cara Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cara Therapeutics, Inc. operates in Biopharmaceuticals / Specialty Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceuticals by Cyborg Score

Browse Biopharmaceuticals / Specialty Therapeutics research →
NEW · MCP server

Ask your AI assistant about Cara Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cara Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Cara Therapeutics, Inc. do this quarter?”
“Is Cara Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Cara Therapeutics, Inc. do?+
Cara Therapeutics is a clinical-stage biopharmaceutical company specializing in novel therapeutics for chronic pruritus and pain by targeting peripheral kappa opioid receptors. The company's lead commercialized produc...
What is Cara Therapeutics, Inc.'s Cyborg Score?+
Cara Therapeutics, Inc. has a Cyborg Score of 4/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cara Therapeutics, Inc.'s main competitors?+
Named competitors include Topical corticosteroids and antihistamines, Gabapentin and pregabalin, Emerging kappa agonist programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Cara Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cara Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cara Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Halozyme Therapeutics, Inc.8Vera Therapeutics, Inc.7AbbVie Inc.7Amneal Pharmaceuticals, Inc.7Arcutis Biotherapeutics, Inc.7BioArctic AB7Biogen Inc.7Bristol-Myers Squibb Company7Immix Biopharma, Inc.7Innovent Biologics, Inc.Top companies in Biopharmaceuticals by Cyborg Score